A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

Inclusion Criteria:

- HbA1c equal to or above 7.0% measured after 26 weeks of treatment in NN5401-3941
(NCT01680341), by central laboratory

Exclusion Criteria:

- Uncontrolled or untreated severe hypertension defined as systolic blood pressure
equal to or above 180 mmHg and/or diastolic blood pressure equal to or above 100 mmHg

- Impaired liver function, defined as alanine aminotransferase (ALAT) or aspartate
aminotransferase (ASAT) equal to or above 2.5 times upper limit of normal

- Impaired renal function defined as serum-creatinine equal to or above 125 micromol/L
(equal to or above 1.4 mg/dL) for males and equal to or above 110 micromol/L (equal
to or above 1.3 mg/dL) for females